Priyanka*, Priyanshu, Monika and Sharma Madhu Suresh Kumar

Department of Pharmacy, AKTU, Lucknow, India

*Corresponding Author: Priyanka, Department of Pharmacy, AKTU, Lucknow, India.

Received: January 15, 2025; Published: January 31, 2025

Abstract

Among heterocyclic compounds, quinoline is an advantage that appears as a significant assembly motive for the development of new drug entities. Quinoline and its derivatives tested with diverse biological activity constitute an important class of compounds for new drug development. Therefore, many scientific communities have developed these compounds as intent structure and evaluated their biological activities. The present, review provides brief natural sources of quinoline and including a new extent of quinoline-based marketed drugs. This review also confers information about the biological activities of quinoline derivatives such as antibacterial, antifungal, antimycobacterial, antiviral, anti-protozoal, antimalarial, anticancer, cardiovascular, CNS effects, antioxidant, anticonvulsant, analgesic, anti-inflammatory, anthelmintic and miscellaneous activities.

Keywords: Anti-Virus; Anti-Tuberculosis; Anti-Oxidation

References

1. X Yang. “Efficient copper-catalyzed synthesis of 4-aminoquinazoline and 2, 4-diaminoquinazoline derivatives”. Synletter 1 (2010): 101-106.
2. Wang D and Gao F. “Quinazoline derivatives: Synthesis and bioactivities”. Chemistry Central Journal 7 (2013): 1-15.
3. Chandregowda V., et al. “Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives”. European Journal of Medicinal Chemistry 44 (2009): 3046-3055.
4. Al-Rashood ST., et al. “Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4 (3H)-quinazolinone analogs”. Bioorganic and Medicinal Chemistry 14 (2006): 8608-8621.
5. Vasdev N., et al. “Synthesis of 6-acrylamido-4- (2-[18F] fluoroanilino) quinazoline: A prospective irreversible EGFR binding probe”. Journal of Labelled Compounds and Radiopharmaceuticals 48 (2005): 109-115.
6. Wakeling AE., et al. “ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy”. Cancer Research 62 (2002): 5749-5754.
7. Rohini R., et al. “Antimicrobial study of newly synthesized 6-substituted indolo[1,2-c] quinazolines”. European Journal of Medicinal Chemistry 45 (2010): 1200-1205.
8. Antipenko L., et al. “Synthesis of new 2-thio- [1,2,4] triazolo[1,5-c] quinazoline derivatives and its antimicrobial activity”. Chemical and Pharmaceutical Bulletin 57 (2009): 580-585.
9. Jatav V., et al. “Synthesis and antimicrobial activity of some new 3-[5- (4-substituted) phenyl-1,3,4-oxadiazole-2yl]-2-styrylquinazoline- 4 (3H)-ones”. Medicinal Chemistry Research 17 (2008): 205-211.
10. Aly AA. “Synthesis of novel quinazoline derivatives as antimicrobial agents”. Chinese Journal of Chemistry 21 (2003): 339-346.
11. Li H., et al. “Synthesis and bioactivity of 4-quinazoline oxime ethers”. Progress in Natural Science 8 (1998): 359-365.
12. Chandrika PM., et al. “Synthesis leading to novel 2,4,6-trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity against THP-1, HL-60 and A375 cell lines”. Indian Journal of Chemistry 48B (2009): 840-847.
13. Panneerselvam P., et al. “Anticonvulsant activity of Schiff bases of 3-amino-6,8-dibromo-2-phenylquinazolin- 4 (3H)-ones”. Indian Journal of Pharmaceutical Sciences 72 (2010): 375-378.
14. Nandy P., et al. “Synthesis and antitubercular activity of Mannich bases of 2-methyl-3H-quinazolin-4-ones”. Indian Journal of Heterocyclic Chemistry 15 (2006): 293-294.
15. Saravanan G., et al. “Synthesis and evaluation of antioxidant activities of novel quinazoline derivatives”. International Journal of Pharmaceutical Sciences and Research 2 (2010): 83-86.
16. Lakhan R., et al. “Studies on 4 (3H)-quinazolinone derivatives as anti-malarials”. Journal of the Indian Chemical Society 64 (1987): 316-318.
17. Hess HJ., et al. “Antihypertensive 2-amino-4 (3H)- quinazolinones”. Journal of Medicinal Chemistry 11 (1968): 130-136.
18. Sasmal S., et al. “Design and optimization of quinazoline derivatives as melanin concentrating hormone receptor 1 (MCHR1) antagonists”. Bioorganic and Medicinal Chemistry Letters 22 (2012): 3157-3162.
19. Alvarado M., et al. “Synthesis and biological evaluation of new quinazoline and cinnoline derivatives as potential atypical antipsychotics”. Chemistry and Biodiversity 3 (2006): 106-117.
20. Malamas MS and Millen J. “Quinazolineacetic acids and related analogs as aldose reductase inhibitors”. Journal of Medicinal Chemistry 34 (1991): 1492-1503.
21. Zayed MF and Hassan MH. “Synthesis and biological evaluation studies of novel quinazolinone derivatives as antibacterial and anti-inflammatory agents”. Saudi Pharmaceutical Journal 22 (2014): 157-162.
22. El-Badry YA., et al. “Synthesis and evaluation of new polysubstituted quinazoline derivatives as potentialantimicrobial agents”. Der Pharma Chemica 4 (2012): 1361-1370.
23. Dave RS., et al. “Synthesis, characterization and antimicrobial activity of new quinazolin- 4 (3H)-oneschiff base derivatives”. Journal of Chemical and Pharmaceutical Research 4 (2012): 4864-4869.
24. Devi KA and Sriram MS. “Synthesis and antimicrobial activity of some quinazolinones derivatives”. International Journal of Drug 4 (2012): 324-327.
25. Kyprianou N. “Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance”. Journal of Urology 169 (2003): 1520-1525.
26. Abida Parvez N., et al. “An updated review: newer quinazoline derivatives under clinical trial”. International Journal of Pharmaceutical and Biological Archive 2 (2011): 1651-1657.
27. Moyer JD., et al. “Induction of apoptosis and cell cycle arrest by CP- 358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase”. Cancer Research 57 (1997): 4838-4848.
28. Asif M. “Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives”. International Journal of Medicinal Chemistry 2014 (2014): 1-27.
29. Zhang J., et al. “A Simple and Efficient Approach to the Synthesis of 2-Phenylquinazolines via sp3 C−H Functionalization”. Organic Letter 12 (2010): 2841-2843.
30. G Chakraborty., et al. “Paul Dehydrogenative synthesis of quinolines, 2-aminoquinolines, and quinazolines using singlet diradical Ni (II)-catalysts”. Journal of Organic Chemistry 84 (2019): 2626-2641.
31. Sarma R., et al. “Microwave-promoted efficient synthesis of dihydroquinazolines”. Green Chemistry 13 (2011): 718-722.
32. DS Deshmukh., et al. “Molecular iodine catalysed benzylic sp3 C-H bond amination for the synthesis of 2-arylquinazolines from 2- aminobenzaldehydes, 2-aminobenzophenones and 2-aminobenzyl alcohols”. Synletter 29 (2018): 979-985.
33. Bisht AS., et al. “Chemistry and activity of quinazoline moiety: A systematic review study”. International Journal of Pharmaceutical Chemistry and Analysis 7 (2020): 61-65.
34. Molecular Operating Environment (MOE). Chemical Computing Group (2019).
35. Swiss Institute of Bioinformatics (SwissADME) (2022).
36. Alireza Barmak., et al. “Synthesis, Structural Studies, and α‑Glucosidase Inhibitory, Antidiabetic, and Antioxidant Activities of 2,3-Dihydroquinazolin- 4 (1H) ones Derived from Pyrazol-4-carbaldehyde and Anilines”. ACS Omega 4 (2019): 18087-
37. Pisoschi A M and Negulescu GP. “Methods for Total Antioxidant Activity Determination: A Review”. Analytical and Bioanalytical Chemistry 1 (2011): 106.
38. Alireza Barmak., et al. “Synthesis, Structural Studies, and α‑Glucosidase Inhibitory, Antidiabetic, and Antioxidant Activities of 2,3-Dihydroquinazolin- 4 (1H)‑ones Derived from Pyrazol-4-carbaldehyde and Anilines”. ACS Omega 4 (2019): 18087-
39. Hatem A Abuelizz., et al. “Molecular Docking and Anticonvulsant Activity of Newly Synthesized Quinazoline Derivatives”. Molecules 22 (2017): 1094.
40. Alagarsamy V., et al. “Synthesis, analgesic, anti-inflammatory and anti-bacterial activities of some novel 2-methyl-3-substituted quinazolin-4 (3H)-ones”. Biological and Pharmaceutical Bulletin 26 (2003): 1711-1714.
41. KM Amin., et al. “Synthesis, biological evaluation and molecular docking of novel series of spiro [ (2H,3H) quinazoline-2,10 - cyclohexan]-4 (1H)- one derivatives as anti-inflammatory and analgesic agents”. European Journal of Medicinal Chemistry 45 (2010): 2117-2131.
42. Ahmed M Alafeefy., et al. “Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives”. European Journal of Medicinal Chemistry 45 (2010): 4947e4952.
43. DL Bilbey., et al. British Journal of Pharmacology and Chemotherapy 4 (1960): 540-543.
44. Ahmed M Alafeefy., et al. “Synthesis, analgesic and anti-inflammatory evaluation of some novel quinazoline derivatives”. European Journal of Medicinal Chemistry 45 (2010): 4947-4952.
45. Fariba Peytam., et al. “Design, synthesis, and evaluation of novel substituted imidazole[1,2-c] quinazoline derivatives as potential α-glucosidase inhibitors with bioactivity and molecular docking insights, scientific report nature. Com”.
46. Shweta Mishra., et al. “Exploration of quinazoline-tethered hydroxamic acid derivatives as HDAC inhibitors for anticancer activity: Design, synthesis, molecular docking, and biological evaluation Results in Chemistry”. 7 (2024): 101253.
47. Alonso C., et al. “Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity”. European Journal of Medicinal Chemistry 149 (2018): 225-237.
48. Yong-Feng Guan., et al. “Design, Synthesis, and Anticancer Activity Studies of Novel Quinoline-Chalcone Derivatives Yong-Feng Guan”. Molecules 26 (2021): 4899.
49. Zahra Emamgholipour., et al. “Synthesis, biological evaluation, and in silico study of novel coumarin-quinazoline analogs as potential Anti-Angiogenesis agents”. Results in Chemistry 11 (2024): 101819.
50. Ali Erguc Mehlika Dilek Altintop., et al. “Synthesis and Biological Evaluation of New Quinoline-Based Thiazolyl Hydrazone Derivatives as Potent Antifungal and Anticancer Agents”. Letters in Drug Design and Discovery 2 (2018): 193-202.
51. Veerachamy Alagarsamya and Urvishbhai S Pathak. “Synthesis and antihypertensive activity of novel 3-benzyl-2-substituted-3H- [1,2,4] triazolo[5,1-b] quinazolin-9-ones”. Bioorganic and Medicinal Chemistry 15 (2007): 3457-3462
52. Caroon JM., et al. “Synthesis and Antihypertensive Activity of a Series of Spiro [1,3,4,6,7,11b-hexahydro-2H-benzo quinolizine2,50 -oxazolidin-20 -oriels”. Journal of Medicinal Chemistry 26 (1983): 1426-1433.

Citation

Citation: Priyanka., et al. “Recent Advances in Quinazoline Derivatives: Synthesis, Biological Activities, and Therapeutic Potential". Acta Scientific Pharmaceutical Sciences 9.2 (2025): 58-69.

Copyright

Copyright: © 2025 Priyanka., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.